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bjectives This randomized, prospective, double-blind, multicenter study compared nephrotoxicity
f the nonionic iso-osmolar contrast media (CM) iodixanol versus the ionic low-osmolar CM ioxag-
ate in patients with chronic renal insufﬁciency undergoing coronary angiography.
ackground The properties of iodinated CM might contribute to the incidence of contrast-induced
ephropathy (CIN).
ethods Patients with renal impairment undergoing coronary angiography were randomly as-
igned to iodixanol (n  72) or ioxaglate (n  74).
esults Baseline characteristics were well-matched between the 2 groups. The predicted risk score
or CIN was similar in the iodixanol and in the ioxaglate groups (11.9  4.1 vs. 11.8  4.1), as was
he use of N-acetylcysteine (70% vs. 73%). The primary end point of the study, median peak in-
rease of serum creatinine from day 0 through day 3 after angiography, did not differ between the
odixanol (0.09 mg/dl; interquartile range 0.00 to 0.30 mg/dl) and the ioxaglate (0.15 mg/dl; inter-
uartile range 0.00 to 0.40 mg/dl; p  0.07) groups. The percentages of patients with a peak in-
rease of serum creatinine 0.5 mg/dl (15.9% in iodixanol vs. 18.2% in ioxaglate), 1.0 mg/dl (1.4%
s. 4.5%), and 25% or 0.5 mg/dl (15.9% vs. 24.2%, respectively) also did not differ signiﬁcantly
etween the 2 groups.
onclusions In high-risk patients undergoing coronary angiographic procedures, use of the
onionic iso-osmolar CM iodixanol does not reduce renal deterioration in patients with renal impair-
ent, compared with the ionic low-osmolar CM ioxaglate. Given that the study was underpowered
o compare nephrotoxicity of the 2 groups under the active medical protection of CIN, a larger ran-
omized study is warranted that will enroll patients with higher risks of CIN under a strict control of
ydration regimens and adjunctive medications. (J Am Coll Cardiol Intv 2009;2:415–21) © 2009 by
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Nephrotoxicity of Contrast Media
416he continuing growth in diagnostic imaging and percutane-
us coronary intervention increases the number of patients
xposed to iodinated contrast agents (1). Contrast-induced
ephropathy (CIN) is the third most common cause of renal
ailure and is associated with morbidity and mortality after
oronary catheterization (1–4). The typical clinical feature of
IN is a transient rise in serum creatinine beginning within
4 h of contrast media (CM) administration, typically reaching
peak within 2 to 3 days and returning to baseline within 2
eeks (2).
The most important risk factor for CIN is pre-existing
hronic renal insufficiency (3). Several other risk factors for
IN have been identified, and a risk scoring has been proposed
3–6). The properties of iodinated CM might contribute to
he incidence of CIN (5,7–15). As compared with ionic
igh-osmolar CM, nonionic low-osmolar contrast media
LOCM) have been associated with less deterioration of renal
unction after angiography in patients with chronic renal impair-
ent (7–10,16). Iodixanol (Visipaque, Nycomed Amersham,
rinceton, New Jersey) is the only available agent in the class of
onionic iso-osmolar contrast media (IOCM) and has been
favorably compared with nonionic
LOCM for renal protection
(17,18). Some studies have sug-
gested that IOCM have a lower
risk than LOCM, but the etiology
of CIN is complex and multi-
factorial, and study results have
been conflicting (9,11–15,19).
Therefore, further research is
needed to investigate the extent
to which IOCM and LOCM
differ in nephrotoxic potential.
Ioxaglate is the only ionic LOMC agent. Several experi-
ental studies on the properties of ionic contrast media
ndicated reduced thrombogenicity (20,21), but these studies
ere not corroborated in clinical investigation (22). Therefore,
t is unclear how the ionic and lower viscous properties of the
OMC ioxaglate relate to CIN risk compared with the
OCM iodixanol.
The ICON (Ionic versus non-ionic Contrast to Obviate
orsening Nephropathy after angioplasty in chronic renal
ailure patients) study compared the nephrotoxicity of the
onionic IOCM iodixanol (Visipaque) with that of the ionic
OCM ioxaglate (Hexabrix, Mallinckrodt, Hazelwood, Mis-
ouri) in high-risk patients with stable chronic renal insuffi-
iency undergoing percutaneous diagnostic or interventional
rocedures using CM.
ethods
tudy population and procedures. This was a randomized,
rospective, controlled, double-blinded multicenter study at 7
bbreviations
nd Acronyms
IN  contrast-induced
ephropathy
M  contrast media
OCM  iso-osmolar contrast
edia
OCM  low-osmolar
ontrast mediaenters in the U.S. and Canada (Appendix). For inclusion, catients were at least 18 years old, scheduled for coronary
ngiography, and had stable renal insufficiency defined as
aving 2 consecutive stable serum creatinine values (1.5
g/dl [132.6 mol/l] and 3.0 mg/dl [265.2 mol/l]), with
he most recent obtained within 24 h before angiography. The
atients were willing and able to return to an acceptable
aboratory facility at 48 to 72 h after the procedure for
aboratory evaluations. Exclusion criteria were pregnancy, lac-
ation, left ventricular ejection fraction 20%, hemodynamic
nstability, acute myocardial infarction, planned staged inter-
entional procedures, participation in any investigational drug
tudy within 30 days before enrollment, allergy to iodinated
M, severe liver disease, jaundice or hematological disease,
cheduling for renal angiography, planned exposure to any CM
ithin 72 h after the procedure, intravascular administration of
M within the previous 5 days, inability or reluctance to return
o an acceptable laboratory facility at 48 to 72 h after the
rocedure, current intake of nephrotoxic drugs (e.g., nonste-
oidal anti-inflammatory drugs except acetylsalicylic acid, phe-
ylbutazone, aminoglycosides, amphotericin B, polymicin,
latinum complexes), and acute deterioration or fluctuation of
enal function. This study was conducted in compliance with
he principles of Good Clinical Practice regulations, and the
rotocol was approved by the institutional review board of each
nstitution. Written informed consent was obtained from each
atient before enrollment.
Patients were randomly assigned to receive either the non-
onic IOCM iodixanol or the ionic LOCM ioxaglate (1:1)
ith sealed envelopes that contained a computer-generated
andomization sequence. N-acetylcysteine was administered at
he discretion of the investigator. Patients received dipheny-
ramine 25 mg intravenously before the procedure as well as
ntravenous one-half isotonic saline at 100 ml/h for at least 3 to
h before the index procedure, throughout the angiographic-
nterventional procedure, and for at least 12 h after CM
dministration (or until discharge if it occurred sooner). So-
ium bicarbonate was not used. Invasive angiography or
ercutaneous coronary intervention was performed according
o the normal practice of the participating institutions. Serum
reatinine was monitored before injection of CM as well as at
2, 24, and 48 to 72 h after injection. Creatinine clearance was
stimated from serum creatinine with the Cockcroft-Gault
ormula (23). A change in post-injection serum creatinine
alues of 0.5 mg/dl (44.2 mol/l) or 25% of the baseline
alues was classified as in-hospital acute renal failure and
ollowed until the serum creatinine value returned to within 5%
f the baseline value or was stable for a period of at least 14
ays. All patients had an electrocardiogram on baseline, im-
ediately after procedure, and on the day of discharge. Cardiac
nzymes were serially collected at baseline as well as at 6, 12,
4, and 48 to 72 h after procedure.
nd points and deﬁnitions. The primary end point of the
tudy was the median peak increase in serum creatinine
oncentration between day 0 (when CM was administered)
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417nd day 3. To assess actual deterioration of renal function, a
ecrease of serum creatinine from baseline was considered
zero increase” of serum creatinine. The secondary end points
ncluded: the proportion of patients with a peak serum creat-
nine increase of 0.5 mg/dl (44.2 mol/l); the proportion of
atients with a peak serum creatinine increase of 1.0 mg/dl
88.4 mol/l); and the proportion of patients with a peak
erum creatinine increase of either0.5 mg/dl or25% from
ay 0 through day 3. Acute renal failure (with or without
ialysis) was defined as a rise in serum creatinine 25% above
he baseline value in the initial 3 days after the index procedure.
on–Q-wave myocardial infarction was defined as a creatine
inase-myocardial band enzyme elevation 3 times the upper
ormal value without new Q waves on the electrocardiogram.
Q-wave myocardial infarction was defined as presence of
ew pathologic Q waves (0.04 s) on an electrocardiogram in
onjunction with an elevation in creatine kinase greater than
wice the normal value. The predicted risk score of CIN was
ssessed on the basis of the patients’ clinical and laboratory
onditions as previously proposed (3). All adverse clinical
vents as well as study end points were monitored and
djudicated by the independent event committee.
tatistical methods. A total sample size of 130 patients was
alculated to have an 80% power to detect a difference of 0.5
D in the mean peak serum creatinine concentrations between
he 2 study groups. In relative terms, 0.5 SD is generally
onsidered to be a moderately small difference. With data from
he NEPHRIC (Nephrotoxicity in High-Risk Patients Study
f Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Me-
ia) study (13), which reported the SD of the peak change in
ean serum creatinine as 0.22 to 0.98 mg/dl, the present study
as designed to have an 80% power to detect differences in the
ange of 0.11 to 0.49 mg/dl in peak serum creatinine between
he 2 groups. During the enrollment into the study, the sample
ize was further increased to 145 patients to allow for loss to
ollow-up.
Continuous variables are presented as mean  SD or
edian with interquartile range (IQR) and compared with
he Student unpaired t test or Wilcoxon rank sum tests
hen the distribution was not normally distributed. Cate-
orical variables are presented as numbers or percentages
nd were compared with chi-square or Fisher exact tests
hen there were 5 values in a given cell. The primary end
oint was analyzed with the Wilcoxon rank sum test, due to
he skewed distribution of the primary study end point. In
ddition, a parametric t test with a normalizing logarithmic
ransformation was conducted for comparison, with no
ignificant differences compared with the nonparametric
ilcoxon rank sum test. A correction factor of 0.1 was
dded to each value before applying the log transform to
eal with zero values of the primary end point. Relative risks
ere analyzed for binary secondary end points. All tests
ere 2-sided at a significance level of 0.05. All statistical Inalyses were carried out with SAS software version 9.1
SAS institute, Cary, North Carolina).
esults
aseline characteristics and procedures. A total of 146
atients were enrolled over a period of 3 years: 72 patients
eceived iodixanol and 74 patients received ioxaglate as
andomly allocated. Adherence to randomization assign-
ent was 100%. The 2 groups had similar demographic and
aseline characteristics as shown in Tables 1 and 2. Baseline
reatinine clearance was 44.5  14.1 ml/min in the iodixa-
ol group and 45.9  18.9 ml/min in the ioxaglate group
p  NS). N-acetylcysteine was administered to 72% of
atients. A predicted mean risk score of CIN was 11.9 
.1 in the iodixanol group and 11.8  4.1 in the ioxaglate
roup (p  NS). High volumes of contrast agent (over 200
l) were administered in 56% of the iodixanol group and in
1% of the ioxaglate group. Both groups were similarly
ell-hydrated, with mean fluid intake of 3.6 l in the
odixanol group and 3.8 liters in the ioxaglate group.
ncrease of serum creatinine. The peak increase in serum
reatinine over time did not differ significantly between the
groups: the primary end point, median increase from
aseline to day 3, was 0.09 (IQR: 0.00 to 0.30) in the
odixanol group versus 0.15 (IQR: 0.00 to 0.40) in the
oxaglate group (p 0.07); and mean respective values were
.20  0.34 mg/dl in the iodixanol group and 0.35  0.76
g/dl in the ioxaglate group (p  0.14) (Table 3).
The values of serum creatinine at baseline, 12 h, 24 h, and
2 h were not statistically different between the 2 groups
Fig. 1). However, the change in serum creatinine from
aseline to day 3 was lower in patients who were adminis-
ered iodixanol (mean: 0.12  0.40 mg/dl vs. 0.31  0.78
g/dl, p  0.083; median: 0.09; IQR: 0.10 to 0.30 vs.
edian: 0.15; IQR: 0.00 to 0.40, p 0.035). There were no
ignificant differences in the incidences of any of the
econdary end points between the 2 groups (Table 3).
n-hospital acute renal failure occurred with similar inci-
ences in the iodixanol (11.1%) and the ioxaglate (17.6%)
roups (relative risk: 0.63; 95% confidence interval: 0.28 to
.43; p  0.35).
dverse events. During hospital stay and out to 30 days
fter the index procedure, the incidences of adverse events in
erms of death, myocardial infarction, and repeat revascu-
arization did not differ between the 2 groups (Table 4).
llergic reactions to CM developed in 5.4% (n  4) in the
oxaglate group and in none of the patients in the iodixanol
roup (p  0.12).
iscussion
he primary finding of this study is that the use of nonionic
OCM iodixanol was not associated with a smaller increase
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418n the peak creatinine value compared with the use of ionic
OCM ioxaglate in patients with chronic renal impairment
ho underwent coronary angiography. However, the mean
eak change in serum creatinine from baseline to day 3 was
ignificantly lower in patients who were administered io-
ixanol.
There is now a consensus that CIN can be defined as an
bsolute rise in serum creatinine of 0.5 mg/dl or more or a
elative rise of 25% or more from baseline at 48 to 72 h after
xposure to CM, in the absence of an alternative explana-
ion for the rise (6). The recent Contrast-Induced Nephrop-
Table 1. Baseline Characteristics
Age (yrs)
Male
History of coronary artery disease
Unstable angina
History of myocardial infarction
History of bypass surgery
History of percutaneous coronary intervention
History of smoking
Hypertension
Hyperlipidemia
Diabetes mellitus
Peripheral vascular disease
History of cerebrovascular accident
History of congestive heart failure
History of exposure to contrast agent
History of contrast-induced nephropathy
Left ventricular ejection fraction
Baseline serum creatinine (mg/dl)
Baseline creatinine clearance (ml/min)
Predictive CIN risk score
Data are mean SD or %.
CIN contrast-induced nephropathy.
Table 2. Medications Related to Index Procedure
N-acetylcysteine
Hydration (l)
Oral
Intravenous
Amount of contrast media (ml)
100
100 and 200
200 and 300
300
Duration of contrast administration (min) 5
Percutaneous coronary interventionData are mean SD or %.thy Consensus Panel recommended using a relative in-
rease in serum creatinine to measure CIN, because this is
ess sensitive to the initial level of renal function at baseline
han an absolute increase (24). Because both absolute and
elative increases have been widely used as definitions of
IN in published studies, we reported the rates of several
ifferent definitions of CIN in the present study to allow
omparison with previous work. The choice of 48 to 72 h as
he window for the last serum creatinine measurement in
he present study followed the recommendation of
ontrast-Induced Nephropathy Consensus Panel (24).
ixanol
 72)
Ioxaglate
(n  74) p Value
 9.9 71.3 12.3 0.86
87.5 87.8 1.00
76.4 78.4 0.84
30.6 32.4 0.86
44.4 39.2 0.62
34.7 25.7 0.28
50.0 38.4 0.18
70.8 51.4 0.02
88.9 86.5 0.80
86.1 78.4 0.28
51.4 40.5 0.25
33.3 20.3 0.09
22.2 13.5 0.19
25.4 25.7 1.00
73.6 74.3 1.00
2.8 1.4 0.62
50.9 49.3 12.2 0.43
 0.34 1.80 0.29 0.23
 14.1 45.9 18.9 0.64
 4.1 11.8 4.1 0.94
nol
72)
Ioxaglate
(n  74) p Value
8 73.0 0.85
3.33 3.78 3.12 0.77
1.27 1.54 1.73 0.06
3.19 2.77 2.59 0.73
123 204 108 0.55
5 19.2 0.36
9 30.1 0.86
9 30.1 0.29
7 20.5 0.67
33.06 48.1 35.5 0.59
7 64.9 0.86Iod
(n
71.6
1.86
44.5
11.9Iodixa
(n 
70.
3.61
1.03
2.94
215
12.
31.
38.
16.
1.14
66.
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419Because the incidence of CIN was 2% in general popula-
ion, randomized studies comparing nephrotoxicities of iodixa-
ol with LOCMs have included patients at an increased risk of
IN and used limited amount of CM (12,13,15). The present
tudy also involved the patients with renal impairment at a
igh risk of CIN. The baseline mean value of serum creatinine
1.83 mg/dl), prevalence of diabetes mellitus (46%), average
mount of CM administered 200 ml, and predictive CIN
isk score (3) were all similar or higher than in previous
andomized studies (12,13,15). This should not be interpreted
s a liberal CM volume use but as treatment of complex
atients that necessitated use of higher CM volume despite
onservation measures. The rates of acute renal failure (18% to
2% during hospital stay) in the present study are consistent
ith this high-risk profile of the study population (3).
Table 3. Peak Increase of Serum Creatinine Between Day 0 and Day 3
Peak increase in serum creatinine (mg/dl), median (IQR) 0
Log-transformed peak increase in serum creatinine with 0.1 factor, mean  SD
Patients with increase in serum creatinine, %
0.5 mg/dl
1.0 mg/dl
25%
25% or 0.5 mg/dl
*p value with Wilcoxon rank sum test. †p value with Student t test.
CI confidence interval; IQR interquartile range.
1
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) Iodixanol (mg/dL)
Ioxaglate (mg/dL)
p=0.25 p=0.
Iodixanol
(mg/dL)
Ioxaglate
(mg/dL)
1.86 ± 0.34
1.80 ±1.80 ± 0.29
1.79 ±
Figure 1. Mean Values of Serum Creatinine at Baseline, 12 H, 24 H, and B
The values were not statistically different as assessed by Student t test betwee
0.035 for the mean and median change in serum creatinine from baseline to day 3 bThe reason for the present finding that the use of iodixanol
id not result in a smaller increase of creatinine as compared
ith the ioxaglate is not certain. One of the possible explana-
ions is that ICON was underpowered to compare a nephro-
oxicity of the 2 groups. In addition, because the studies had
ifferent protocols and definitions, the results of our study
annot be directly compared with those of previous studies.
nother plausible explanation is that LOCM and IOCM
ffect renal function to a similar degree. The recently published
andomized CARE (Cardiac Angiography in Renally Im-
aired Patients) study (25), supported this hypothesis, finding
hat the incidence of serum creatinine25% was 12.4% in 210
odixanol patients and 9.8% in 204 LOCM iopamidol patients
p  0.44). Similarly, in a subset analysis of the randomized
ONTRAST (Fenoldopam Mesylate for the Prevention of
ixanol Ioxaglate
Difference
(95% CI)
Relative Risk
(95% CI) p Value
00 to 0.30) 0.15 (0.00 to 0.40) NA NA 0.07*
1 0.82 1.34 0.93 0.27 (0.56 to 0.03) NA 0.08†
5.9 18.2 2.2% (16.5 to 12.0) 0.88 (0.42 to 1.85) 0.82
1.4 4.5 3.1% (10.4 to 4.2) 0.32 (0.03 to 2.99) 0.36
5.9 24.2 8.3% (23.4 to 6.8) 0.66 (0.33 to 1.31) 0.28
5.9 24.2 8.3% (23.4 to 6.8) 0.66 (0.33 to 1.31) 0.28
24 72
mes (hr)
p=0.38
p=0.62
1.93 ± 0.44 2.13 ± 0.97
1.89 ± 0.38 1.99 ± 0.55
n 24 and 72 H After the Index Procedure
iodixanol and ioxaglate groups at each period. The p values are 0.083 andIod
.09 (0.
1.6
1
1
1Ti
86
 0.34
 0.37
etwee
n the
etween the iodixanol and ioxaglate groups, respectively.
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420ontrast-Induced Nephropathy) trial, the incidence of CIN
as similar with IOCM iodixanol compared with LOCM
gents (33.3% vs. 25.3%; p  0.39) (26).
However, in the NEPHRIC (Nephrotoxicity in High-Risk
atients Study of Iso-Osmolar and Low-Osmolar Non-Ionic
ontrast Media) study, among 129 patients with diabetes and
aseline renal insufficiency undergoing cardiac and aorto-
emoral angiography, iodixanol was associated with signifi-
antly lower rates of CIN than iohexol (13). Use of a different
OCM (iohexol, having osmolarity higher than of ioxaglate
780 mOsm/kg vs. 580 mOsm/kg]) for the control group in
ssessing the benefit of iodixanol might have contributed to the
utcomes of that study. The incidence of a serum creatinine
ncrease 1.0 mg/dl was 15% in the iohexol group (control of
he NEPHRIC study), but the incidence was 4.5% in the
odixanol group (control of the present study). The iodixanol
roups, however, did not show a striking difference in the
ncidence of the serum creatinine increase1.0 mg/dl between
he NEPHRIC trial (0%) and the present study (1.5%) (13).
urthermore, definitions of the primary end point in the 2
tudies were not the same. Whereas the primary end point of
he NEPHRIC study was based on the absolute change in
erum creatinine from baseline to peak, the primary end point
Table 4. In-Hospital and 30-Day Adverse Clinical Events
In-Hospital Events
Iodixanol Ioxaglate
p Value(n  72) (n  74)
Death 2 (2.8%) 0 (0%) 0.24
Cardiac 1 (1.4%) 0 (0%) 0.49
Renal 0 (0%) 0 (0%) —
Other 1 (1.4%) 0 (0%) 0.49
Myocardial infarction 0 (0%) 1 (1.4%) 1.00
Q-wave 0 (0%) 0 (0%) —
Non–Q-wave 0 (0%) 1 (1.4%) 1.00
Repeat revascularization 1 (1.4%) 0 (0%) 0.49
Percutaneous 0 (0%) 0 (0%) —
Bypass surgery 1 (1.4%) 0 (0%) 0.49
Overall events 3 (4.2%) 1 (1.4%) 0.36
30-Day Events (n  70) (n  74)
Death 4 (5.7%) 1 (1.4%) 0.20
Cardiac 3 (4.3%) 1 (1.4%) 0.36
Renal 0 (0%) 0 (0%) —
Other 1 (1.5%) 0 (0%) 0.49
Myocardial infarction 0 (0%) 1 (1.4%) 1.00
Q-wave 0 (0%) 0 (0%) —
Non–Q-wave 0 (0%) 1 (1.4%) 1.00
Revascularization 2 (2.9%) 1 (1.4%) 0.61
Percutaneous 1 (1.4%) 0 (0%) 0.49
Bypass surgery 1 (1.4%) 1 (1.4%) 1.00
Overall events 6 (8.6%) 3 (4.2%) 0.32
Data are n (%).f the present study was the peak increase in serum creatinine nrom baseline. However, as noted, the absolute change in
erum creatinine in our study was significantly less in the
odixanol group, consistent with the NEPHRIC study.
More recently, the RECOVER (REnal toxicity evaluation
nd COmparison between Visipaque and HExabrix in patients
ith Renal insufficiency undergoing coronary angiography)
tudy, which used the same CM as our study, presented a less
ephrotoxic effect of the iodixanol than the ioxaglate in 300
atients with renal impairment (15). The incidence of CIN,
efined as an increase of serum creatinine 25%, was 7.9% in
he iodixanol group and 17.0% in the ioxaglate group (p 
.021). There was an interesting difference in the protocols
etween the 2 randomized studies (RECOVER and NEPH-
IC) and the present study. Only 8.5% of patients in the
EPHRIC study and none in the final analysis of the
ECOVER study were treated with N-acetylcysteine. In our
tudy, however, the drug was administered to 72% of patients.
lthough the data on N-acetylcysteine are not yet substantial
nough to warrant strong recommendation of the drug in
ational guidelines, the benefit in preventing CIN has been
eported in several randomized trials and meta-analyses
27–29). Therefore, a less restricted use of N-acetylcysteine in
he present study might have had an effect on the result. The
andomized CARE study (25) and a registry study (14), which
id not avoid use of N-acetylcysteine, showed a similar
ncidence of CIN with either iodixanol or LOCMs.
Vigorous hydration before and after the procedure in the
resent study might further affect outcomes. Prophylactic
ntravenous saline hydration, beginning 12 h before CM
xposure, has been shown to reduce the incidence of CIN (5).
atients in the present study were hydrated with one-half
ormal saline before, during, and after the procedure, receiving
mean of approximately 3.7 l of fluid in total. In contrast, the
atients in the NEPHRIC study received a mean intravenous
uid 1 l (13). In the RECOVER study, patients received
aline hydration at 1 ml/kg/h for at least 8 h before and after
he procedure, but no data were presented to show whether the
olume of hydration was equivalent between the 2 treatment
roups (15).
The use of a central core biochemistry laboratory to measure
erum creatinine would certainly strengthen the conclusions of
he study. Also, there is still a possibility that the present study
as underpowered to compare a nephrotoxicity of the 2 groups
nder the active medical protection of CIN. This limitation
oupled with the diversity in results among the NEPHRIC,
ECOVER, CARE, and ICON trials warrants a new ran-
omized study in which more patients with higher risks of
IN are enrolled under a strict control of hydration regimens
nd adjunctive medications.
onclusions
he results of the present study indicated that use of the
onionic IOCM iodixanol might not reduce renal deterio-
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421ation in patients with renal impairment after coronary
ngiography compared with the ionic LOCM ioxaglate. It
emains important that a combined approach with low-dose
M, use of N-acetylcysteine, adequate hydration, and
iscontinuation of nephrotoxic agent is considered in pa-
ients at a high risk of CIN.
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APPENDIX
TUDY CENTERS AND INVESTIGATORS
Center (Number of Enrolled Patients) Investigator
Lenox Hill Hospital, New York, NY (50) Roxana Mehran, MD
Columbia University Hospital, New York, NY (44) George D. Dangas, MD, PhD
Scripps Clinic, San Diego, CA (19) Paul S. Teirstein, MD
Weill-Cornell Medical College, New York, NY (10) S. Chiu Wong, MD
Moses Cone Heart and Vascular Center,
Greensboro, NC (13)
William E. Downey, MD
St. Michaels Hospital, Toronto, Ontario,
Canada (8)
Wayne B. Batchelor, MD, MHScomparison between visipaque (iodixanol) and hexabrix (ioxaglate) in
patients with renal insufficiency undergoing coronary angiography: the
LDS Hospital, Salt Lake City, UT (2) Peter J. Casterella, MD
